Agnelli G, Iorio A, De Angelis V, Nenci GG. Dermatan sulphate in heparin-induced thrombocytopenia [letter]. Lancet 344:1295-1296,1994.

Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 64:376-381,1993.

Ambühl PM, Wüthrich RP, Korte W, Schmid L, Krapf R. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant 12:2355-2364, 1997.

Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 38:25-29, 2004.

Basmadjian D, Sefton MV, Baldwin SA. Coagulation on biomaterials in flowing blood: some theoretical considerations. Biomaterials 18:1511-1522, 1997.

Bauersachs RM, Lindhoff-Last E, Ehrly AM, Betz C, Geiger H, Hauser IA. Treatment of hirudin overdosage in a patient with chronic renal failure. Thromb Haemost 81: 323-324,1999.

Beijering RJR, ten Gate H, Nurmohamed MT, ten Cate JW. Anticoagulants and extracorporeal circuits. Semin Thromb Hemost 23:225-233, 1997.

Benz K, Nauck MA, Böhler J, Fischer KG. Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use. Clin J Am Soc Nephrol, 2007; in press.

Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 72:381-386,1996.

Berry CN, Lunven C, Girardot C, Lechaire I, Girard D, Charles MC, Ferrari P, O'Brien DP. Ecarin clotting time: a predictive coagulation assay for the anti-thrombotic activity of argatroban in the rat. Thromb Haemost 79:228-233,1998.

Bichler J, Gemmerli R, Fritz H. Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons. Thromb Res 61:39-51, 1991.

Blaufox MD, Hampers CL, Merrill JP. Rebound anticoagulation occurring after regional heparinization for hemodialysis. ASAIO Trans 12:207-209, 1966.

Boccardo P, Melacini D, Rota S, Mecca G, Boletta A, Casiraghi F, Gianese F. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure. Nephrol Dial Transplant 12:2349-2354, 1997.

Boon DMS, van Vliet HHDM, Zietse R, Kappers-Klunne MC. The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb Haemost 76:480, 1996.

Bredlich RO, Stracke S, Gall H, Proebstle TM. Heparin-associated platelet aggregation syndrome with skin necrosis during haemodialysis. Dtsch Med Wochenschr 122:328-332, 1997.

Bucha E, Nowak G, Czerwinski R, Thieler H. r-Hirudin as anticoagulant in regular hemodialysis therapy: finding of therapeutic r-hirudin blood/plasma concentrations and respective dosages. Clin Appl Thromb Hemost 5:164-170,1999a.

Bucha E, Kreml R, Nowak G. In vitro study of r-hirudin permeability through membranes of different haemodialyzers. Nephrol Dial Transplant 14:2922-2926,1999b.

Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfrac-tionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 58:279-285, 1997.

Carrier M, Knoll GA, Kovacs MJ, Moore JC, Fergusson D, Rodger MA. The prevalence of antibodies to the platelet factor 4-heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res [Epub ahead of print] 10 Nov, 2006.

Chang JJ, Parikh CR. When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients. Semin Dial 19:297-304, 2006.

Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 22:85-91, 1992.

Danhof M, De Boer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations of Orgaran (Org 10172) therapy. Haemostasis 22:73-84, 1992.

de Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother 37:1237-1240, 2003.

De Sancho M, Lema MG, Amiral J, Rand J. Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialy-sis [letter]. Thromb Haemost 75:695-696, 1996.

Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 96:2373-2378, 2000.

Finazzi G, Remuzzi G. Heparin-induced thrombocytopenia—background and implications for haemodialysis. Nephrol Dial Transplant 11:2120-2122, 1996.

Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemost 28:4674-4682, 2002.

Fischer KG, van de Loo A, Böhler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int 56 (suppl 72): S46-S50,1999.

Fischer KG, Weiner SM, Benz K, Nauck M, Böhler J. Treatment of hirudin overdose with hemofiltration [abstr]. Blood Purif 18:80-81, 2000.

Fischer KG, Liebe V, Hudek R, Piazolo L, Haase KK, Borggrefe M, Huhle G. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost 89:973-982, 2003.

Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS. Regional hemodialysis anti-coagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis 27:519-524, 1996.

Frank RD, Farber H, Stefanidis I, Lanzmich R, Kierdorf HP. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. Kidney Int 56 (suppl 72):S41-S45, 1999.

Frank RD, Farber H, Lazmich R, Floege J, Kierdorf HP. In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes. Nephrol Dial Transplant 17:1957-1963, 2002.

Greinacher A, Drost W, Michels I, Leitl J, Gottsmann M, Kohl HJ, Glaser M, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. Ann Hematol 64:402, 1992a.

Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 67:545-549, 1992b.

Greinacher A, Philippen KH, Kemkes-Matthes B, Möckl M, Mueller-Eckhardt C, Schaefer K. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis. Nephrol Dial Transplant 8:1176-1177, 1993.

Greinacher A, Zinn S, Wizemann U, Birk W. Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis. Lancet 348:764, 1996.

Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocy-topenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846-851, 2000.

Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108:2062-2065, 2003.

Griessbach U, Sturzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 37:347-350, 1985.

Grötsch H, Hropot M. Degradation of rDNA hirudin and a-human thrombin hirudin complex in liver and kidney homogenates from rat. Thromb Res 64:763-767, 1991.

Gupta AK, Kovacs MJ, Sauder DN. Heparin-induced thrombocytopenia. Ann Pharmac-other 32:55-59, 1998.

Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 22:169-176, 2006.

Haas G. Versuche der Blutauswaschung am Lebenden mit Hilfe der Dialyse. Klin Wochenschr 4:13-14, 1925.

Haase M, Bellomo R, Rocktaeschel J, Ziemer S, Kiesewetter H, Morgera S, Neumayer HH. Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrol Dial Transplant 20:444-446, 2005.

Hafner G, Peetz D, Klingel R, Prellwitz W. Methods for hirudin determination in plasma. J Lab Med 24:172-178, 2000.

Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost 28:425-430, 2002.

Hall AV, Clark WF, Parbtani A. Heparin-induced thrombocytopenia in renal failure. Clin Nephrol 38:86-89, 1992.

Hartman V, Malbrain M, Daelemans R, Meersman P, Zachee P. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 104:c143-c148, 2006.

Hein OV, von Heymann C, Morgera S, Konertz W, Ziemer S, Spies C. Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure. Artif Organs 29:507-510, 2005.

Henny CP, ten Cate H, ten Cate JW, Surachno S, Van Bronswijk H, Wilmink JM, Ockelford PA. Use of a new heparinoid as anticoagulant during acute haemodialy-sis of patients with bleeding complications. Lancet 1:890-893, 1983.

Hertel J, Keep DM, Caruana RJ. Anticoagulation. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 3d ed. Boston: Little, Brown, pp. 182-198, 2001.

Horellou MH, Conard I, Lecrubier C, Samama M, Roque-D'Orbcastel O, de Fenoyl O, Di Maria G, Bernadou A. Persistent heparin induced thrombocytopenia despite therapy with low molecular weight heparin [letter]. Thromb Haemost 51:134, 1984.

Huhle G, Hoffmann U, Wang L, Bayerl C, Harenberg J. Allergy and positive IgG in a patient reexposed to r-hirudin [abstr]. Ann Hematol 76 (suppl 1):A97, 1998.

Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 106:195-201,1999.

Huhle G, Liebe V, Hudek R, Heene DL. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma half-life. Thromb Haemost 85:936-938, 2001.

Janson PA, Moake JL, Carpinito G. Aspirin prevents heparin-induced platelet aggregation in vivo [letter]. Br J Haematol 53:166-168, 1983.

Janssen MJFM, Deegens JK, Kapinga TH, Beukhof JR, Huijgens PC, Van Loenen AC, Van der Meulen J. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 49:806-813,1996.

Kadidal VV, Mayo DJ, Home MK. Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases. J Intern Med 246:325-329,1999.

Kappa JR, Fisher CA, Berkowitz HD, Cottrel ED, Addonizio VP. Heparin-induced platelet activation in sixteen surgical patients: diagnosis and management. J Vasc Surg 5:101-109,1987.

Kern H, Ziemer S, Kox WJ. Bleeding after intermittent or continuous r-hirudin during CVVH. Intensive Care Med 25:1311-1314, 1999.

Koide M, Yamamoto S, Matsuo M, Suzuki S, Arima N, Matsuo T. Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 10:2137-2140,1995.

Koster A, Merkle F, Hansen R, Loebe M, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 91: 265-269, 2000.

Laster J, Elfrink R, Silver D. Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg 9:677-682, 1989.

Leblanc M, Roy LF, Legault L, Dufresne LR, Morin C, Thuot C. Severe skin necrosis associated with heparin in hemodialysis. Nephron 68:133-137, 1994.

Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocy-topenia and thrombosis syndrome. Semin Thromb Hemost 23:197-202, 1997.

Liebe V, Piazolo L, Fischer KG, Hudek R, Heene DL, Huhle G. A monoclonal mouse anti-r-hirudin antibody neutralizes r-hirudin in vivo—potential use as antidote [abstr]. Ann Hematol 80 (suppl 1):A42, 2001.

Lindhoff-Last E, Betz C, Bauersachs R. Use of a low molecular weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost 7:300-304, 2001.

Lubenow N, Greinacher A. Heparin-induced thrombocytopenia. Recommendations for optimal use of recombinant hirudin. Biodrugs 14:109-125, 2000.

Lunven C, Gauffeny C, Lecoffre C, O'Brien DP, Roome NO, Berry CN. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 75:154-160, 1996.

Luzzatto G, Bertoli M, Cella G, Fabris F, Zaia B, Girolami A. Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 89:115-122,1998.

Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 70:554-561,1993.

Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95:967-981, 2006.

Markwardt F. Past, present and future of hirudin. Haemostasis 21:11-26, 1991.

Matsuo T, Nakao K, Yamada T, Matsuo O. Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit. Thromb Res 41:33-41, 1986.

Matsuo T, Yamada T, Chikahira Y, Kadowaki S. Effect of aspirin on heparin-induced thrombocytopenia (HIT) in a patient requiring hemodialysis. Blut 59:393-395, 1989.

Matsuo T, Kario K, Kodama K, Okamoto S. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Semin Thromb Hemost 18:155-160,1992.

Matsuo T, Kario K, Nakao K, Yamada T, Matsuo M. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 23:135-141, 1993.

Matsuo T, Koide M, Kario K. Application of argatroban, a direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation. Artif Organs 21:1035-1038, 1997.

Matsuo T, Kusano H, Wanaka K, Ishihara M, Dyama H. Heparin-induced thrombocy-topenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Haemost 13:182-187, 2007.

Moberg PQ, Geary VM, Sheikh FM. Heparin-induced thrombocytopenia: a possible complication of heparin-coated pulmonary artery catheters. J Cardiothorac Anesth 4:226-228, 1990.

Müller A, Huhle G, Nowack R, Birck R, Heene DL, van der Woude FJ. Serious bleeding in a haemodialysis patient treated with recombinant hirudin. Nephrol Dial Transplant 14:2482-2483, 1999.

Mon C, Moreno G, Ortiz M, Diaz R, Herrero JC, Oliet A, Rodriguez I, Ortega O, Gallar P, Vigil A. Treatment of hirudin overdosage in a dialysis patient with heparin-induced thrombocytopenia with mixed hemodialysis and hemofiltration treatment. Clin Nephrol 66:302-305, 2006.

Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, Tang I, Hursting MJ, Shamp TR, Swan SK. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66:2446-2453, 2004.

Nakamoto H, Shimada Y, Kanno T, Wanaka K, Matsuo T, Suzuki H. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial Int 9 (suppl 1):S2-S7, 2005.

Neuhaus TJ, Gotschel P, Schmugge M, Leumann E. Heparin-induced thrombocytope-nia type II on hemodialysis: switch to danaparoid. Pediatr Nephrol 14:713-716, 2000.

Newman PM, Swanson RL, Chong BH. IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 80:292-297, 1998.

Novacek G, Kapiotis S, Jilma B, Quehenberger P, Michitsch A, Traindl O, Speiser W. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin. Thromb Res 88:283-290, 1997.

Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 22:197-202,1996.

Nowak G, Bucha E, Gööck T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 66:707-715,1992.

Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 109: 354-358,1997.

Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, Berends F, Hommes DW, Rijnierse JJMM, Sturk A. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. Thomb Haemost 72: 685-692, 1994.

Oh JJ, Akers WS, Lewis D, Ramaiah C, Flynn JD. Recombinant factor Vila for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 26:569-577, 2006.

Ortel TL, Gockermann JP, Califf RM, McCann RL, O'Connor CM, Metzler DM, Greenberg CS. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin-induced thrombocytopenia and thrombosis. Thromb Haemost 67:292-296, 1992.

O'Shea SI, Sands JJ, Nudo SA, Ortel TL. Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol 69:72-73, 2002.

O'Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 16:61-67, 2003.

Ota K, Akizawa T, Hirasawa Y, Agishi T, Matsui N. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 18:1623-1630, 2003.

Palomo I, Pereira J, Alarcon M, Diaz G, Hidalgo P, Pizarro I, Jara E, Rojas P, Quiroga G, Moore-Carrasco R. Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal 19:189-195, 2005.

Peña de la Vega L, Miller RS, Benda MM, Grill DE, Johnson MG, McCarthy JT, McBane RD 2nd. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 80: 995-1000, 2005.

Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate anticoagulation for hemo-dialysis in the patient at high risk for bleeding. N Engl J Med 308: 258-261, 1983.

Polgár J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 91:549-554,1998.

Pöschel KA, Bucha E, Esslinger HU, Nörtersheuser P, Jansa U, Schindler S, Nowak G, Stein G. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure. Kidney Int 58:2478-2484, 2000.

Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [letter]. N Engl J Med 343:515, 2000.

Roe SD, Cassidy MJD, Haynes AP, Byrne JL. Heparin-induced thrombocytopenia (HIT) and thrombosis in a haemodialysis-dependent patient with systemic vasculitis. Nephrol Dial Transplant 13:3226-3229, 1998.

Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 39:1601-1605, 2005.

Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 37:652-654, 2003.

Romao JE Jr, Fadil MA, Sabbaga E, Marcondes M. Haemodialysis without anticoagulant: haemostasis parameters, fibrinogen kinetic, and dialysis efficiency. Nephrol Dial Transplant 12:106-110, 1997.

Roussi JH, Houbouyan LL, Goguel AF. Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications [letter]. Lancet 1:1183, 1984.

Rylance PB, Gordge MP, Ireland H, Lane DA, Weston MJ. Haemodialysis with prostacyclin (epoprostenol) alone. Proc Eur Dial Transplant Assoc Eur Renal Assoc 21:281-286, 1985.

Samuelsson O, Amiral J, Attman P-O, Bennegard K, Björck S, Larsson G, Tengborn L. Heparin-induced thrombocytopenia during continuous haemofiltration. Nephrol Dial Transplant 10:1768-1771, 1995.

Saner F, Hertl M, Broelsch CE. Anticoagulation with hirudin for continuous veno-venous hemodialysis in liver transplantation. Acta Anaesthesiol Scand 45:914-918, 2001.

Schmitt GW, Moake JL, Rudy CK, Vicks SL, Hamburger RJ. Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Platelet activation and factor VII-related von Willebrand factor during hemodialysis. Am J Med 83:411-418, 1987.

Schneider SA, Nauck MS, Nauck MA, Fischer KG. Only plasmapheresis allows for danaparoid elimination from blood. Kidney Blood Press Res 27:360, 2004.

Schneider T, Heuer B, Deller A, Boesken WH. Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocy-topenia (HIT II). Wien Klin Wochenschr 112:552-555, 2000.

Selleng K, Selleng S, Raschke R, Schmidt CO, Rosenblood GS, Greinacher A, Warkentin TE. Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. Am J Hematol 78:188-192, 2005.

Sitter T, Spannagl M, Banas B, Schiffl H. Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 79:245-246, 1998.

Smith MC, Danviriyasup K, Crow JW, Cato AE, Park GD, Hassid A, Dunn MJ. Prostacyclin substitution for heparin in long-term hemodialysis. Am J Med 73: 669-678, 1982.

Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 100:1528-1532,1999.

Sreedhara R, Itagaki I, Lynn B, Hakim RM. Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 25:555-563, 1995.

Steuer S, Boogen C, Plum J, Deppe C, Reinauer H, Grabensee B. Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytope-nia. Nephrol Dial Transplant 14 (suppl 4):45-47,1999.

Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20: 318-329, 2000.

Takahashi H, Muto S, Nakazawa E, Yanagiba S, Masunaga Y, Miyata Y, Tamba K, Kusano E, Matsuo M, Matsuo T, Asano Y. Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient. Clin Nephrol 59:458-462, 2003.

Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 39:231-236, 2005.

Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocy-topenia. Nephrol Dial Transplant 12:2750-2755,1997.

Turney JH, Williams LC, Fewell MR, Parsons V, Weston MJ. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 2:219-222, 1980.

Unver B, Sunder-Plassmann G, Hörl WH, Apsner R. Long-term citrate anticoagulation for high-flux haemodialysis in a patient with heparin-induced thrombocytopenia type II. Acta Med Austriaca 29:146-148, 2002.

Vanholder RC, Camez AA, Veys NM, Soria J, Mirshahi M, Soria C, Ringoir S. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 45:1754-1759, 1994.

Vanholder R, Camez A, Veys N, van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 77:650-655, 1997.

Van Wyk V, Badenhorst PN, Luus HG, Kotze HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 48:1338-1343,

0 0

Post a comment